       Document 0502
 DOCN  M9630502
 TI    Long-term treatment of diseased, FIV-seropositive field cats with
       azidothymidine (AZT).
 DT    9603
 AU    Hart S; Nolte I; Clinic of Small Animals, Hanover School of Veterinary
       Medicine,; Germany.
 SO    Zentralbl Veterinarmed A. 1995 Aug;42(6):397-409. Unique Identifier :
       AIDSLINE MED/96092121
 AB    The long-term effectiveness of Azidothymidine (AZT, Zidovudine) was
       evaluated in FIV-seropositive cats with clinical symptoms (n = 9; Group
       1) compared with conventional symptomatical therapy (n = 5; Group 2).
       The oral administration of Azidothymidine at a dosage of 5 mg/kg BW
       yielded a mean peak plasma concentration of 4.59 microM one hour after
       application (median: 3.74 microM). Elimination half time was 1.5 h. The
       permanent oral application of Azidothymidine at a dosage of 5 mg/kg BW
       TID led to a total recovery from clinical symptoms in six of nine
       FIV-seropositive cats (Group 1) 4-6 weeks after the onset of therapy.
       One cat clinically improved with only sporadical recurrence of disease;
       therapy with Azidothymidine was not effective in two cats. All the
       FIV-seropositive cats treated symptomatically responded well to
       antibiotics and immunomodulators within 10-14 days (n = 5; Group 2).
       Recurrence of clinical symptoms was noticed in three of five patients
       within 2 years after therapy and one cat died. During the treatment with
       Azidothymidine hyperproteinemia and abnormal albumin-to-globulin ratio
       became normal within 6 months in four FIV positive cats (Group 1),
       whereas hyperproteinemia did not change in Group 2. The following
       adverse effects were noticed in Group 1: a transient decrease of red
       blood cell count (RBC), packed cell volume (PCV) and haemoglobin until
       the 4th week of application of Azidothymidine (5/8), but the haemogram
       was within the normal range after 3 months. In one cat with
       hyperglycemia the anaemia remained until the administration of
       Azidothymidine was terminated. Heinz (Schmauch) bodies in the
       erythrocytes appeared in two FIV-positive cats 2 weeks after the onset
       of the therapy.
 DE    Administration, Oral  Animal  Antiviral Agents/ADMINISTRATION &
       DOSAGE/*THERAPEUTIC USE  Cats  Feline Acquired Immunodeficiency
       Syndrome/*DRUG THERAPY  Female  *Immunodeficiency Virus, Feline  Male
       Time Factors  Treatment Outcome  Zidovudine/ADMINISTRATION &
       DOSAGE/*THERAPEUTIC USE  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

